EUVIMEDEUVIMED entdecken
Crossref

Development and Evaluation of a Leflunomide-Loaded Nanoemulgel for Transdermal Delivery in Rheumatoid Arthritis: A Preclinical Study

Neha Gupta, Abdul Rahaman Shaik, Ananda Kumar Chettupalli

Current Drug Therapy · 02.07.2026 · 21

DOI: 10.2174/0115748855416618251208101849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Drug Therapy, erschienen am 02.07.2026. Verfasst von Neha Gupta und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Leflunomide (LFM), a disease-modifying antirheumatic agent, is constrained by inadequate aqueous solubility and systemic side effects upon oral administra-tion. To address these limitations, we sought to develop a nanoemulsion-based gel (nanoemulgel, NEG) for transdermal administration to improve local therapeutic efficacy in Rheumatoid Arthritis (RA).

Method

A series of LFM nanoemulsions was produced utilizing isopropyl myristate, Cremo-phor® EL, and Transcutol® P, and optimized via pseudo-ternary phase diagrams. The chosen formulation (LFM-NE7) was integrated into a Carbopol-940 gel matrix to produce the NEG. The improved formulation was assessed for particle size, zeta potential, in vitro drug release, ex vivo skin penetration, and in vivo anti-arthritic efficacy in Wistar rats.

Results

The optimized LFM-NEG displayed a droplet size of 75.98 ± 3.24 nm, zeta potential of –15.5 ± 0.18 mV, and drug permeation of 85.62 ± 2.18 μg/cm². In vivo, 28-day topical administration of LFM-NEG significantly reduced paw edema, improved hematological pa-rameters, and suppressed pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) compared to conventional gel and disease control groups.

Discussion

Drug transporters from NE had small particles, narrow PDI, and anti-zeta. NE surfactant and co-surfactant ratios affected particle size, drug release viscosity, and the amount of drug released. The formula particle size and medicine release were modified by olive oil structure and proportion (10%). NE may circumvent the stratum corneum and allow medications to reach their targets, according to in vitro and in vivo drug permeability/deposition studies.

Conclusion

This study presents, for the first time, an effective formulation of a leflunomide-loaded nanoemulgel as a viable transdermal system for the treatment of rheumatoid arthritis, enhancing drug permeation, bioavailability, and localized anti-inflammatory efficacy while minimizing systemic side effects.

Zitieren

APA

Gupta, N., Shaik, A. R., & Chettupalli, A. K. (2026). Development and Evaluation of a Leflunomide-Loaded Nanoemulgel for Transdermal Delivery in Rheumatoid Arthritis: A Preclinical Study. Current Drug Therapy, 21. https://doi.org/10.2174/0115748855416618251208101849

Vancouver

Gupta N, Shaik AR, Chettupalli AK. Development and Evaluation of a Leflunomide-Loaded Nanoemulgel for Transdermal Delivery in Rheumatoid Arthritis: A Preclinical Study. Current Drug Therapy. 2026;21. doi:10.2174/0115748855416618251208101849

BibTeX
@article{Gupta2026,
  author = {Gupta, Neha and Shaik, Abdul Rahaman and Chettupalli, Ananda Kumar},
  title = {Development and Evaluation of a Leflunomide-Loaded Nanoemulgel for Transdermal Delivery in Rheumatoid Arthritis: A Preclinical Study},
  journal = {Current Drug Therapy},
  year = {2026},
  volume = {21},
  doi = {10.2174/0115748855416618251208101849}
}
Kostenlos starten →